 PLANEGG and MUNICH, GERMANY ACCESSWIRE April 6, 2020 MorphoSys AG MORPrime Standard Segment; MDAX TecDAXMOR provided an update on its business and the measures the Company is taking to mitigate the impact of the rapidly evolving global COVID-19 pandemic on its employees, patients and the broader community. The well-being of our employees and patients is our top priority, said Jean-Paul Kress, M.D., CEO and Chairman of the MorphoSys Management Board. While we are working closely with the sites and our investigators to mitigate the impact of the COVID-19 pandemic on our clinical studies and to continue delivering the medicines our patients desperately need, we are putting their safety and that of the site personnel first. 